Issue Date: January 5, 2009
GSK Signs Aptamer Deal With Archemix
GlaxoSmithKline has linked with Archemix to develop aptamer therapeutics, or synthesized oligonucleotides, against seven targets related to inflammatory diseases. GSK is taking a $6.5 million stake in Archemix, which recently announced a merger with fellow Boston-area biotech firm NitroMed. Archemix also gains an additional $21 million upfront and could receive up to $200 million in milestone payments for each of the seven aptamer targets covered in the deal. The biotech firm will be tasked with developing the aptamer therapeutics through clinical proof-of-mechanism.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society